EGFR and bladder transitional cell carcinoma: In particular, sq-BLCA appears to be a subtype to not only provide the most cumulative treatment options, but also hypothetically offer many different drug combinations (Figure 6E) considering, for instance, the close association between EGFR and Trop-2 (Table S1).